stockrowOrganon & Co.
OGNHealthcare Drug Manufacturers General
Organon & Co.’s revenue for fiscal 2025 (year ended December 2025) was $6.2 billion, down 2.92% from fiscal 2024.
- Revenue
- −1.75%
- EPS
- +1.64%
- Free cash flow
- +118.8%
- Total debt
- −3.10%
Quarter to September 2026, against a year earlier
Follow OGN
Alert me
Organon & Co. (OGN) EPS (diluted)
Organon & Co.'s EPS (diluted) for fiscal 2025 was $0.72, down 78.4% from $3.33 in fiscal 2024. Over the twelve months to 30 September 2026 it was $0.76. Over the past ten years it has ranged from $0.72 (fiscal 2025) to $12.69 (fiscal 2019) — the current reading is the lowest in ten years. Organon & Co. ranks 13th of 20 Drug Manufacturers General companies by EPS (diluted).
EPS (diluted), annual
Embed this chart
Annual newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| FY2025 | $0.72 | (78.38%) |
| FY2024 | $3.33 | (16.54%) |
| FY2023 | $3.99 | 11.14% |
| FY2022 | $3.59 | (32.39%) |
| FY2021 | $5.31 | (37.68%) |
| FY2020 | $8.52 | (32.88%) |
| FY2019 | $12.69 | 49.16% |
| FY2018 | $8.51 | 19.69% |
| FY2017 | $7.11 | — |
Quarterly newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| Sep 2026 | $0.60 | 50.00% |
| Jun 2026 | $0.40 | (27.27%) |
| Mar 2026 | $0.55 | — |
| Dec 2025 | −$0.79 | — |
| 23 more quarters | Free account |
Against its own ten years
EPS (diluted) against peers
| Company | EPS (diluted) |
|---|---|
| BMY Bristol Myers Squibb Company compare | $4.51 |
| NVO Novo Nordisk A/S compare | $3.97 |
| GSK GSK PLC Sponsored ADR compare | $2.98 |
| BIIB Biogen Inc. compare | $2.34 |
| SNY Sanofi compare | $2.02 |
| OGN Organon & Co. | $0.76 |
| PFE Pfizer Inc. compare | $0.71 |
| GRFS Grifols, S.A. compare | $0.46 |
| AMRN Amarin Corporation PLC compare | −$0.92 |
What EPS (diluted) is
Diluted EPS tells an investor how much profit a company earned for each share, counting the extra shares that options and convertible securities could create.
Reported line item
More on OGN
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement